Tijdschr Diergeneesk
-
Tijdschr Diergeneesk · Feb 1989
Review[Medical hemostasis. II. Systemic hemostatics, a critical evaluation].
The control of spontaneous and traumatic haemorrhage is a matter of constant concern to veterinary practitioners. In some instances, the control of bleeding may be relatively simple using some topical therapeutic procedure, but when haemostatic defects are present, treatment with topical agents alone might not be sufficient, and more radical and life-saving procedures are indicated: replacement therapy with blood or blood products. As this is not easy to perform in most veterinary clinical situations, any therapeutic agent, which facilitates control of haemorrhage is a welcome addition to the therapeutic armament. ⋯ Double-blind prospective trials with quantitation of loss of blood showed that antifibrinolytic agents such as tranexamic acid are clinically effective in certain conditions in humans. Because of their mode of action, it might reasonably be expected that these drugs might have positive results in veterinary medicine. Therefore, clinical trials with antifibrinolytic agents are urgently indicated to evaluate the effectiveness and side-effects of these drugs in animals showing severe bleeding or in the prevention of peroperative haemorrhage.
-
Tijdschr Diergeneesk · Feb 1989
Review[Medical hemostasis. I. the treatment of hemorrhages and hemorrhagic diathesis in veterinary practice].
Bleeding patients are regularly encountered, often as an emergency, in veterinary practice. In many cases local causes will be responsible for the bleeding, but in some there will be a generalised haemostatic defect. The approach to the bleeding patient, suspected of a generalised haemostatic defect, requires a detailed history and careful physical examination in order to differentiate between hereditary and acquired haemostatic disorders and, in the case of an acquired haemostatic disorder, to detect which underlying disease caused the defect and which parts of the haemostatic system are involved. ⋯ Diagnosis, local treatment and replacement therapy with plasma or blood(products) are discussed. Drugs which are contra-indicated in bleeding patients, are also referred to. The second paper will critically evaluate the commercially available haemostatics.